In the last trading session, 3.24 million shares of the Bone Biologics Corporation (NASDAQ:BBLG) were traded. Most recently the company’s share price was $0.18, and it changed around $0.01 or 9.09% from the last close, which brings the market valuation of the company to $3.26M. BBLG currently trades at a discount to its 52-week high of $1.97, offering almost -994.44% off that amount. The share price’s 52-week low was $0.14, which indicates that the current value has risen by an impressive 22.22% since then. We note from Bone Biologics Corporation’s average daily trading volume that its 10-day average is 2.12 million shares, with the 3-month average coming to 447.11K.
Bone Biologics Corporation stock received a consensus recommendation rating of a Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended BBLG as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Bone Biologics Corporation is expected to report earnings per share of -$0.16 for the current quarter.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Bone Biologics Corporation (NASDAQ:BBLG) trade information
Instantly BBLG has showed a green trend with a performance of 9.09% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.2138 on Tuesday, 05/23/23 increased the stock’s daily price by 15.81%. The company’s shares are currently down -14.16% year-to-date, but still down -6.69% over the last five days. On the other hand, Bone Biologics Corporation (NASDAQ:BBLG) is -28.66% down in the 30-day period. We can see from the shorts that 0.11 million shares have been sold at a short interest cover period of 0.39 day(s).
The consensus price target as assigned by Wall Street analysts is $4.50, which translates to bulls needing to increase their stock price by 96.0% from its current value. Analyst projections state that BBLG is forecast to be at a low of $2.25 and a high of $6.75. In order for the stock price to hit the forecast high, the stock would need to plunge -3650.0% from its current level, while the stock would need to crash -1150.0% from its current level to reach the projected low.
Bone Biologics Corporation (BBLG) estimates and forecasts
Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will loss -128.60% in revenue this quarter, and will report a decrease of -100.00% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 50.80%.
Bone Biologics Corporation’s next quarterly earnings report is expected to be released in June.
Bone Biologics Corporation (NASDAQ:BBLG)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 40.14% of Bone Biologics Corporation shares, and 18.31% of them are in the hands of institutional investors. The stock currently has a share float of 30.59%. Bone Biologics Corporation stock is held by 14 institutions, with Sabby Management, LLC being the largest institutional investor. By Mar 30, 2023, it held 8.98% of the shares, which is about 1.5 million shares worth $0.27 million.
Walleye Capital LLC, with 4.83% or 0.81 million shares worth $0.15 million as of Mar 30, 2023, holds the second largest percentage of outstanding shares.
The former held 5900.0 shares worth $1062.0, making up 0.04% of all outstanding shares.